Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, September 23, 2014

New MS Therapy From Biogen Idec, AbbVie Reveals Positive Phase 3 Results in RRMS Patients

biogen idec and abbviePhase 3 clinical trial results from Biogen Idec and AbbVie presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRMIS) suggest that relapsing-remitting multiple sclerosis patients experience symptom relief when given monthly subcutaneous injections of ZINBRYTA (daclizumab high-yield process)
Patients saw a statistically significant reduction in disease activity when compared to patients treated with the established treatment, AVONEX (interferon beta-1a).
“The full results from DECIDE demonstrate that ZINBRYTA significantly improved key measures of multiple sclerosis disease activity compared to AVONEX, including reducing annualized relapse rate and new brain lesion development,” said Ludwig Kappos, MD, lead investigator of the DECIDE trial, in a news release from Biogen Idec. “These results help us better understand ZINBRYTA as a potential treatment option for people with relapsing-remitting MS.”
This positive data was generated through the two- to three-year, phase 3 study of more than 1,800 relapse-remitting multiple sclerosis patients from 28 countries. Patients were given either 150 mg subcutaneous ZINBRYTA every four weeks or 30 mcg intramuscular AVONEX once weekly.
Upon compiling and analyzing the results, the research team found a statistically significant 45% reduction in annualized relapse rate in patients treated with ZINBRYTA — 73% of patients were relapse-free, while only 59% of those on AVONEX were relapse-free. These patients also had fewer enlarging brain lesions and a better performance on the Expanded Disability Status Scale.

 Keep CURRENT and up to date, with MS News and Information
Sign-up for our Bi-Monthly eNewsletters 



No comments: